【摘要】 代谢相关脂肪性肝病（MAFLD）是与IR、遗传易感性密切相关的代谢紊乱性肝脏疾病，病理学改变以肝细胞脂肪变性为主。近年来，MAFLD患病率显著升高，应尽早干预。GLP-1受体激动剂通过促进Ins释放和改善IR发挥降糖作用，并且MAFLD患者的体重、脂质代谢、炎症反应及纤维化等有显著改善，有望成为治疗MAFLD的有效药物。更多还原

【Abstract】 Metabolic associated fatty liver disease(MAFLD) is a metabolic disorder liver disease closely related to insulin resistance(IR) and genetic susceptibility. Hepatocyte steatosis is the main pathological change. In recent years,the prevalence of MAFLD has increased significantly,so it is necessary to provide interventions as soon as possible. Glucagon-like peptide-1 receptor agonist plays a hypoglycemic effect by promoting insulin release and reducing IR. Studies shows that it has significant benefits on body weight,lipid metabolism,inflammation and fibrosis in patients with MAFLD,and is expected to be an effective drug for the treatment of MAFLD.更多还原